A practical reference on 研究代号: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
== Hepatalin Action == The human body stores nutrient energy that it gets from meals by partitioning it between fats and glycogen. Hepatalin acts selectively on muscle, heart, and kidneys to store nutrient energy as glycogen. Hepatalin does not act on the liver or fat cells (adipocytes) or intestines. Insulin acts mainly on fat cells and the liver, storing fat in fat depots throughout the body, and glycogen and fat in the liver. In a healthy state, the majority of glucose uptake is accounted for by hepatalin action in muscle. In response to an intravenous injection of insulin after a meal, hepatalin action accounted for approximately 55% of the glucose uptake (in rats) and 66% (in humans). The partitioning of the nutrient energy storage process in a healthy body is dependent on the ratio of insulin and hepatalin action. If hepatalin action is decreased, glucose levels after a meal rise higher and for longer, and the pancreas must secrete much more insulin to manage the nutrient processing. Nutrient partitioning shifts from glycogen in muscle to lipids, with elevated blood and organ triglycerides resulting. If hepatalin action is reduced chronically, the metabolic consequences account for the predictable, chronological development of the dysfunctions known to be associated with the metabolic syndrome aka syndrome X. It has been proposed that hepatalin is the missing link in understanding and managing obesity, prediabetes, and type 2 diabetes. Hepatalin action decreases with age, is worsened by a sugar supplemented diet.
== Research == The steroidal antiandrogen cyproterone acetate has been studied for blocking the testosterone flare at the start of buserelin therapy in men with prostate cancer. While cyproterone acetate for two weeks eliminates the biological and biochemical signs of the flare, no benefits on prostate cancer outcomes were observed. Very low doses of buserelin nasal spray have been assessed for increasing testosterone levels and fertility in men with oligoasthenozoospermia and hypogonadotropic hypogonadism.
== History == Artificial ligament research began in the World War I era. In the first documented case of an artificial ligament in 1914, Dr. Corner utilized a piece of silver filament as synthetic graft to reconstruct a ruptured anterior cruciate ligament (ACL). A ligament made of silk was used to replace an ACL in 1918. In the early 1980s, technological progress in chemistry and materials science promoted the development of medically suitable materials. Doctors utilized these synthetic materials in clinical applications. The Food and Drug Administration (FDA) approved an artificial ligament made of Gore-Tex for use in ACL reconstruction in 1986. The design of artificial ligaments in the 1980s consisted of two major parts: a relatively stiff cable or tape, and silicone rubber cylinders on one or both ends. The cable or tape was usually made of polyethylene, nylon or carbon fiber. The silicone rubber cylinder varied in size to fit different sized patients. Theoretically, the flexibility of the silicone rubber would allow some deformation under relatively low loads, and the artificial ligament would stiffen to maintain its shape under higher loads. Practically, this design never achieved its goal to mimic the property of a natural ligament. The mechanical performance of the artificial ligaments was inadequate for widespread clinical application. In the long term, performance loss, complications, and failure occurred. Material deterioration contributed to the ineffectiveness of early artificial ligaments. Issues would occur in the months and years following treatment. J.E.
Sources: en.wikipedia.org
This is in contrast to many progestins, such as 19-nortestosterone derivatives (e.g., norethisterone, levonorgestrel, dienogest) and 17α-hydroxyprogesterone derivatives (e.g., cyproterone acetate, medroxyprogesterone acetate), which do bind to the AR and have been associated with significant androgenic or antiandrogenic effects depending on the progestin in question. Due to its lack of androgenic and antiandrogenic activity, and hence lack of masculinizing and feminizing effects, progesterone is one of the few progestogens that is suitable for use during pregnancy in women at risk for preterm birth or recurrent miscarriage.
==== Same-sex marriage ==== On June 14, 2004, the Cherokee Nation Tribal Council voted to officially define marriage as a union between a woman and man, thereby excluding same-sex marriage. This decision came in response to an application by a lesbian couple submitted on May 13. On December 9, 2016, same-sex marriage was legalized through an opinion by Todd Hembree, the Cherokee Nation's attorney general. In the opinion, Hembree stated that the 2004 law violated the Cherokee Constitution, which requires equal treatment of tribal citizens. He issued the opinion because the director of the tribe's tax commission sought a decision as to whether the tribe could issue a vehicle tag to a same-sex couple married outside the tribe's jurisdiction.
Evidence of the use of dye in pottery are found in most cases on the upper part of ceramic basins, on the inside surface, the areas in which the reduced dye-solution was exposed to air, and underwent oxidation that turned it purple. In the Late Bronze Age Hala Sultan Tekke on Cyprus was a major exporter of purple-dyed textiles with the dye coming from the mucus gland of the murex sea snail. The production of Murex purple for the Byzantine court came to an abrupt end with the sack of Constantinople in 1204, the critical episode of the Fourth Crusade. David Jacoby concludes that "no Byzantine emperor nor any Latin ruler in former Byzantine territories could muster the financial resources required for the pursuit of murex purple production. On the other hand, murex fishing and dyeing with genuine purple are attested for Egypt in the tenth to 13th centuries." By contrast, Jacoby finds that there are no mentions of purple fishing or dyeing, nor trade in the colorant in any Western source, even in the Frankish Levant. The European West turned instead to kermes dye provided by the insect Kermes vermilio, known as grana, or crimson. In 1909, Harvard anthropologist Zelia Nuttall compiled an intensive comparative study on the historical production of the purple dye produced from the carnivorous murex snail, source of the royal purple dye valued higher than gold in the ancient Near East and ancient Mexico.
Sources: en.wikipedia.org
== Vapor-ion, charge transfer reaction == The analytes are in the vapor phase. This includes breath, odors, VOCs, and other molecules with low volatility that, due to the constant improvements in sensitivity, are detectable in the vapor phase despite their low vapor pressure. Analyte ions are produced via gas-phase chemical reactions, where charging agents collide with the analyte molecules and transfer their charge. In secondary electro-spray ionization (SESI), a nano-electrospray operated at high temperature produces nanodroplets that evaporate very rapidly to produce ions and protonated water clusters that ionize the vapors of interest. SESI is commonly used for the analysis of trace concentrations of vapors being able to detect low volatility species in the gas phase with molecular masses of up to 700 Da.
== Plot == The Combine have opened an interdimensional portal in place of the destroyed Citadel, to summon reinforcements and defeat the Resistance. Outside City 17, Gordon Freeman and Alyx Vance escape the wreckage of a train they used to flee the city. They proceed to a transmission station, where they make contact with Dr. Isaac Kleiner and Dr. Eli Vance, who have arrived at the White Forest rocket facility. Kleiner and Eli learn that a copied Combine transmission Alyx is carrying may be able to close the portal. Gordon and Alyx reach an abandoned mine, where Alyx is critically wounded by a Combine Hunter. A vortigaunt leads them to an underground outpost, where Gordon is instructed to help gather larvae from an antlion colony to heal Alyx. After the larvae are gathered, vortigaunts begin to heal Alyx. With their abilities diverted, the G-Man can now connect to Gordon. He reveals that he rescued Alyx from Black Mesa during the Resonance Cascade, and that it is imperative she reaches White Forest. The G-Man instructs an unconscious Alyx to tell Eli to "prepare for unforeseen consequences". After Alyx recovers, they reunite with Eli, Kleiner and her pet robot, Dog, at White Forest and are introduced to Dr. Arne Magnusson. The scientists are preparing a rocket which they plan to use with the code to reverse the portal. After Gordon subdues a Combine attack on the facility, Alyx gives Kleiner a message recorded by Judith Mossman, which contains the location of the Borealis, a vanished Aperture Science research vessel.
=== Polymerization === The ring-opening polymerization of butyrolactone gives polybutyrolactone. The resulting reverts to the monomer by thermal cracking. It is claimed that poly(GBL) is competitive with commercial biomaterial poly(4-hydroxybutyrate), or P4HB. It is further claimed that poly(GBL) is cheaper to make than P4HB, although both are bio-derived.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。